Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Japanese descent with all 2 biological parents of Japanese descent * On hemodialysis (HD) or hemodiafiltration (HDF) with single-pool Kt/V (spKt/V) ≥1.2, using arteriovenous (AV) fistula or AV graft ≥3 months prior to Screening 1 at a healthcare center, and is on the same dialysis regimen ≥2 weeks prior to Screening 1 * Be judged to plan to continue or anticipate the use of the current AV fistula or AV graft until the poststudy visit Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * On peritoneal dialysis or other dialysis modalities except for HD and HDF * History of deep vein thrombosis or pulmonary embolism * History of vascular access thrombosis within 1 month prior to Screening 1 * Personal or family history of bleeding disorder * History of GI bleeding, duodenal polyps or active gastroduodenal ulcer within 5 years prior to Screening 1, or history of severe hemorrhoidal bleed within 3 months prior to Screening 1 * History of frequent epistaxis within 3 months prior to Screening 1 or active gingivitis * At the time of screening or predose, planned significant dental procedures, or other planned surgical procedures within duration of participation in the trial * History of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (IVIG) or a brand of Rho(D) immune globulin (RhoGAM) within 1 year prior to …